After the SELECT trial cardiovascular indication for Wegovy (FDA approved March 2024) and the SURMOUNT-OSA approval for Zepbound (December 2024), Aetna added separate coverage pathways for those medical indications, which often bypass the obesity carve-outs
Rapid injection can cause localized pain and may affect absorption consistency
10.1016/j.neurobiolaging.2010.02.014 331
Industry Funding: From the study, the funder was Eli Lilly and Company, which provided the study drug and was involved in study design, data collection, data analyses, data interpretation, and writing of the report
Receptors for this hormone, i.e., proteins on the surface of cells that react with it, are abundant in the hypothalamus, particularly in the arcuate nucleus region
10.1016/j.biopha.2022.113078 56 LouH.FuW.ChenJ.LiT.JiangY.LiuC.et al (2021)